Dufrane Denis, Marchal Christophe, Cornu Olivier, Raftopoulos Christian, Delloye Christian
University Tissue Bank, Université catholique de Louvain, Brussels, Belgium.
J Neurosurg. 2003 Jun;98(6):1198-202. doi: 10.3171/jns.2003.98.6.1198.
Allogenic human fascia lata used in neurosurgery as a dura mater substitute can be associated with the risk of virus and bacterium transmission and with a delay in its incorporation due to immunological and inflammatory reactions. The authors review their preliminary experience with a chemically and physically processed fascia lata graft.
Grafts that had been treated with solvent detergents, freeze-dried for conservation, and gamma irradiated (25,000 Gy) for sterilization were placed into 17 patients during neurosurgical procedures performed to treat brain tumors, cerebral malformations, trigeminal neuralgia, and posttraumatic lesions. The handling properties of the material, surgical wound features, and hematological parameters were evaluated. The average follow-up period was 23.8 +/- 2.2 months (mean +/- standard deviation). The handling properties and biocompatibility of these human dural substitutes were highly satisfactory and no major complications were observed. Postoperative computerized tomography or magnetic resonance images obtained in 13 patients revealed no abnormal findings at the site of fascia lata implantation. In one patient who underwent a second surgery performed 12 months after the initial operation, this dural substitute was found to have been recolonized by host fibroblastic cells and replaced by autologous collagenous tissue.
Human fascia lata that has been rendered safe by applying physical and chemical treatment is a fully biocompatible alternative to the dural graft materials currently available.
在神经外科手术中用作硬脑膜替代物的同种异体人阔筋膜可能存在病毒和细菌传播风险,并且由于免疫和炎症反应,其整合过程会延迟。作者回顾了他们使用化学和物理处理的阔筋膜移植物的初步经验。
将经过溶剂洗涤剂处理、冷冻干燥保存并经伽马射线辐照(25,000戈瑞)灭菌的移植物,在治疗脑肿瘤、脑畸形、三叉神经痛和创伤后病变的神经外科手术过程中植入17例患者体内。评估了材料的操作特性、手术伤口特征和血液学参数。平均随访期为23.8±2.2个月(平均值±标准差)。这些人硬脑膜替代物的操作特性和生物相容性非常令人满意,未观察到重大并发症。13例患者术后的计算机断层扫描或磁共振图像显示阔筋膜植入部位无异常发现。在一名初次手术后12个月接受二次手术的患者中,发现这种硬脑膜替代物已被宿主成纤维细胞重新定植,并被自体胶原组织替代。
经过物理和化学处理而变得安全的人阔筋膜是目前可用的硬脑膜移植材料的完全生物相容性替代品。